Scarica l'app Stockscreener
2.36
2.61%
0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
Invus and Avicenna holdings disclosed in Neumora Therapeutics (NASDAQ: NMRA) filing - Stock Titan
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Neumora Therapeutics (NMRA) price target increased by 19.25% to 9.33 - MSN
Stifel Maintains Neumora Therapeutics (NMRA) Hold Recommendation - MSN
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pr - Benzinga
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
NMRA Technical Analysis | Trend, Signals & Chart Patterns | NEUMORA THERAPEUTICS INC (NASDAQ:NMRA) - ChartMill
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Neumora Therapeutics (NASDAQ: NMRA) sets 2026 proxy votes on board, auditor and executive pay - Stock Titan
Neumora Therapeutics (NMRA) is among the best penny stocks set to explode - MSN
Neumora Therapeutics (NMRA) Stock Turns Bearish on Neumora Therapeutics (NMRA) (+1.48%) 2026-04-15Risk Management - Cổng thông tin điện tử tỉnh Lào Cai
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
NMRA Q4 2025 Earnings: Neumora Therapeutics misses EPS estimates, reports no revenuePopular Market Picks - Cổng thông tin điện tử tỉnh Lào Cai
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode - Insider Monkey
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Rally Mode: Is Neumora Therapeutics Inc forming a breakout patternInflation Watch & Growth Oriented Trade Recommendations - baoquankhu1.vn
Short Squeeze: Does Neumora Therapeutics Inc stock have upside surprise potentialEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Is Neumora Therapeutics (NMRA) Stock Good for Long Term | Price at $2.12, Up 6.00%Community Buy Signals - UBND thành phố Hải Phòng
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat
ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake - Stock Titan
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Guggenheim - The Globe and Mail
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead - TipRanks
Loss Report: Will Neumora Therapeutics Inc benefit from geopolitical trendsQuarterly Market Summary & Trade Opportunity Analysis - baoquankhu1.vn
Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $6 to $18 - Moomoo
Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Neumora Therapeutics Reports Strong 2025 Financials and Clinical Pipeline Progress Including NMRA-511 Alzheimer’s Agitation Data and KOASTAL-2/3 Enrollment 123 - Minichart
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access - TipRanks
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% By Investing.com - Investing.com India
Guggenheim reiterates Neumora stock rating on pipeline progress By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Neumora Therapeutic (NMRA.US) will release its earnings report before the market opens on March 30. - Moomoo
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics 2025 Financial Update - AlphaStreet
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):